Lars Rebien Sørensen

Last updated • 2 min readFrom Wikipedia, The Free Encyclopedia

Lars Rebien Sørensen
Lars-rebien-sorensen.jpg
Born (1954-10-10) October 10, 1954 (age 69)
EducationThe Royal Veterinary and Agricultural University, University of Copenhagen.
Occupation(s)Former CEO at Novo Nordisk, chair of Novo Nordisk Foundation (2020
EmployerNovo Nordisk (until 2016)

Lars Rebien Sørensen (born 10 October 1954) is a Danish businessman and former CEO of the pharmaceutical company Novo Nordisk and current chairman of the board at the Novo Nordisk Foundation (from 2018) and Novo Holdings A/S.

Contents

Biography

Education

Lars Rebien Sørensen is a MSc forestry graduate [1] from the Royal Veterinary and Agricultural University, now part of the University of Copenhagen (1981) and holds a master's degree from Copenhagen Business School (1983). [2] [1]

Career

He was employed by Novo Nordisk in 1982 within marketing of enzymes and became sales and marketing director for the enzyme department in 1989. He joined the Group Executive Board of Novo Nordisk in 1994 and was handed the responsibility of the medical department of Novo Nordisk. In 2000 the enzyme department was de-merged from Novo Nordisk and became its own entity, Novozymes, and Lars Rebien Sørensen took over the position of CEO for Novo Nordisk, after Mads Øvlisen. In January 2017, Lars Rebien Sørensen was succeeded as CEO by Lars Fruergaard Jørgensen. [3] As part of his severance package, Sørensen received a "golden handshake" of 65.7 million DKK (approx. US$10.7 million). His annual salary in 2016 was 22.7 million DKK (approx. US$3.7 million). [4]

He was CEO at Novo Nordisk from 2000 until the end of 2016 and was replaced by Lars Fruergaard Jørgensen at the beginning of 2017. [5]

Lars Rebien Sørensen took on the position as chairman of the board at Novo Nordisk Foundation on 1 July 2018. He is also the chairman of the board at Novo Holdings A/S. [6] The Novo Nordisk Foundation is one of the largest foundations in the world and the foundation which is the majority shareholder in Novo Nordisk, Novozymes and NNIT (Novo Group) along with investments in more than 80 other companies within the life-sciences sector through its 100% owned subsidiary Novo Holdings A/S.

Lars Rebien Sørensen was a representative in the Danish Central bank and he holds a seat at the board of directors in Axcel Management A/S, Thermo Fisher Scientific Inc. (USA), Essity AB (Sweden), Jungbunzlauer Suisse AG (Switzerland) and Novo Holdings A/S. [6]

Board member positions

Lars Rebien Sørensen currently holds the following board member seats: [6]

Private life

Lars Rebien Sørensen is married to Charlotte Idin Sørensen and they have three children.[ citation needed ]

Recognition

Lars Rebien Sørensen was awarded the "World's Best CEO" by Harvard Business Review in 2015 and 2016. [7] [1] [8]

Related Research Articles

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.

<span class="mw-page-title-main">Nordisk Film</span> Danish film company

Nordisk Film A/S is a Danish entertainment company established in 1906 in Copenhagen by filmmaker Ole Olsen. It is the fourth-oldest film studio in the world behind the Gaumont Film Company, Pathé, and Titanus, and the oldest studio to be continuously active.The logo consists of a polar bear standing on the globe.

<span class="mw-page-title-main">Novo Nordisk</span> Danish pharmaceutical company

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.

DSV A/S is a Danish transport and logistics company offering global transport services by road, air, sea and train. Since its foundation in 1976 by nine independent Danish hauliers, the company has achieved rapid expansion and international presence, predominantly through a series of strategic competitor acquisitions, some of the most important ones being Samson Transport (1997), DFDS Dan Transport Group (2000), J.H.Bachmann (2004), Frans Maas (2006), ABX LOGISTICS (2008), UTi Worldwide, Inc. (2016), Panalpina Welttransport (Holding) AG (2019) and Agility Global Integrated Logistics (GIL) (2021).

<span class="mw-page-title-main">Novozymes</span> Danish Biotechnology Company

Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.

FIH Erhvervsbank A/S is the sixth-largest bank in Denmark in terms of total assets. FIH is an integrated corporate and investment bank, offering selected services within capital and advisory services to Danish corporates and operates internationally under the name “Finance for Danish Industry”. FIH is headquartered in Copenhagen and operates from four local offices in Jutland. Year-end 2010, FIH had a total lending of approximately DKK [60] billion spread on roughly 4.000 corporate clients.

<span class="mw-page-title-main">Viborg Katedralskole</span> School in Viborg, Denmark

{{Infobox school | name = Viborg Katedralskole | native_name = | image = | image_size = | alt = | caption = | logo = VkLogo.jpg | motto = Vitam Impendere Vero | established = ca. 1060 | closed = | type = | status = | category_label = | category = | gender_label = | gender = | affiliation = | affiliations = | administrator = | assst_admin = | president = | chairman_label = | chairman = | rector = Helge Markussen | principal = | campus_director = | headmaster = | head_name = Second Master | head = | head_name2 = Assistant Headmaster | head2 = | dean = | founder = | chaplain = | officer_in_charge = | faculty = | teaching_staff = | enrollment = About 1150 | grades_label = | grades = | streetaddress = Gl. Skivevej 2 | city = Viborg | state = | province = | country = Denmark | coordinates = | latitude = | longitude = | district = | oversight = | accreditation = | campus = | colors = | colours = | athletics = | houses = | student_union = | nickname = | mascot = | free_label = [[Embl

<span class="mw-page-title-main">DR Byen</span> Building in Copenhagen, Denmark

DR Byen is the headquarters of the Danish Broadcasting Corporation, DR, located in Copenhagen, Denmark, in the northwestern part of Amager. The first employees moved into DR Byen in 2006 and 2007, but the entire building, including the Koncerthuset Concert Hall, was not completed until 2010. The construction industry's enormous budget overruns have been widely discussed, and were also one of the main reasons of former CEO Kenneth Plummer's announcement on March 13, 2007, that 521 positions would be cut, and that 300 employees would be dismissed. DR Byen replaced Radiohuset in Frederiksberg and TV-Byen in Søborg.

<span class="mw-page-title-main">Steen Riisgaard</span>

Steen Riisgaard is the former president and CEO of the Denmark-based biotech company Novozymes, the world’s largest producer of industrial enzymes. He held this position from when Novozymes was founded in a demerger from Novo Nordisk in 2000 until he left the company in 2013 when Peder Holk Nielsen became CEO.

<span class="mw-page-title-main">Lars Kolind</span> Danish businessman

Lars Kolind is a Danish businessman. Kolind holds an M.Sc. in Mathematics from Aarhus University from 1972 and a B.Comm. from the Copenhagen Business School from 1977. He is adjunct professor of leadership and strategy at Aarhus University Business School since 2000. He serves as Detao Master of Leadership and Strategy since 2012.

The Rigmor and Carl Holst-Knudsen Award for Scientific Research is one of Denmark's oldest and most prestigious science prizes. It was established in 1956, on the birthday of Carl Holst-Knudsen, who was at that time the Chairman of the Board at Aarhus University. Originally worth 10 thousand Danish krones (DKK), it has grown to 100 thousand DKK in monetary value, and is awarded on 28 May annually. It is given without application "as a mark of respect", to a researcher who has produced one or more significant results which show promise in future research.

<span class="mw-page-title-main">Nordisk Fjer</span>

Nordisk Fjer, formerly named Nordisk Fjerfabrik A/S, was a Danish feather processing company established in 1901 and existing until 1991. It was founded in Svendborg by Hans Ove Lange, but moved to Copenhagen during its rapid expansion in the interwar period. During its existence, it traded and cleaned feathers for use in the duvet and furniture industries. The company peaked economically in 1989 with a revenue of 400 million USD, employing 4300 people in 12 countries. In 1991 the company folded in one of the largest Danish corporate scandals.

<span class="mw-page-title-main">Novo Holdings A/S</span> Danish holding company

Novo Holdings A/S is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2023 was worth almost DKK 1,114 billion. Danish Kroner and is the largest charitable foundation in the world making Novo Holdings A/S a world-leading life sciences investor. Novo Holdings A/S is headquartered in Copenhagen, Denmark, with offices in San Francisco, Boston and Singapore.

<span class="mw-page-title-main">Netcompany</span>

Netcompany is a Danish publicly traded IT consultancy headquartered in Copenhagen, Denmark. Since its founding in 2000, the company has grown, both domestically and internationally, into a company with 10 offices across 6 different countries.

<span class="mw-page-title-main">Novo Nordisk Foundation</span> International foundation for medical treatment and research

The Novo Nordisk Foundation is an international enterprise foundation focusing on medical treatment and research.

Kasim Kutay is a British fund manager who is the CEO of Danish Novo Holdings A/S, an investment fund that manages investments and assets for the Novo Nordisk Foundation. He holds British citizenship and resides in Denmark.

<span class="mw-page-title-main">Lemvigh-Müller</span> Danish wholesaler

Lemvigh-Müller is the largest wholesaler of steel and technical installations in Denmark, with over 400,000 different products in its range, +1,400 employees, and an annual turnover of 9.33 billion DKK.

Mads Krogsgaard Thomsen is a Danish businessman, CEO of the Novo Nordisk Foundation and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk.

<span class="mw-page-title-main">Lars Fruergaard Jørgensen</span> Danish businessman (born 1966)

Lars Fruergaard Jørgensen is a Danish businessman, the Chief Executive of Novo Nordisk since January 2017 and Chairman of the European Federation of Pharmaceutical Industries and Associations.


The Novozymes Prize is an annual scientific award. The prize aims to recognise outstanding contributions to the advancement of science within the fields of biotechnology and bioinnovation.

References

  1. 1 2 3 Communication, UCPH (14 March 2017). "'World's best CEO' named distinguished alumnus at the University of Copenhagen". news.ku.dk. Retrieved 24 September 2021.
  2. "Lars Rebien Sørensen". CBS – Copenhagen Business School. 9 July 2020. Retrieved 24 September 2021.
  3. "Lars Rebien Sørensen to retire as CEO of Novo Nordisk". September 2016. Retrieved 24 September 2021.
  4. "Remuneration Report 2020" (PDF). Retrieved 24 September 2021.
  5. "Lars Fruergaard Jorgensen, Novo Nordisk A/S: Profile and Biography". Bloomberg.com. Retrieved 24 September 2021.
  6. 1 2 3 "Lars Rebien Sørensen". Novo Holdings. Retrieved 24 September 2021.
  7. "Novo Nordisk CEO named world's best" . Retrieved 24 September 2021.
  8. "This Big Pharma Chief Was Just Named the World's 'Best-Performing' CEO—Again". Fortune. Retrieved 24 September 2021.